Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.50 |
| ▸ | TDO2 | P48775 | 7/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HAT1 | O14929 | 1/20 | 0.46 |
| ▸ | EP300 | Q09472 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 2/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14147111 | 0.88 | KDM4E (0.57) | GPR84ALDH1A1KMT2AKDM4EHTR2A | |
| SCHEMBL25742050 | 0.85 | GPR84 (0.45) | GPR84TDO2ALDH1A1KMT2AKDM4E | |
| SCHEMBL13533568 | 0.83 | NR4A2 (0.63) | ALDH1A1KMT2AKDM4EHAT1EP300 | |
| SCHEMBL25742056 | 0.82 | HAT1 (0.47) | GPR84TDO2HAT1EP300 | |
| SCHEMBL2818109 | 0.82 | KDM4E (0.66) | GPR84TDO2ALDH1A1KMT2AKDM4E | |
| SCHEMBL30417250 | 0.82 | KDM4E (0.66) | GPR84TDO2ALDH1A1KMT2AKDM4E | |
| SCHEMBL3174938 | 0.81 | NR4A2 (0.49) | ALDH1A1KMT2ANR4A2 | |
| SCHEMBL3188134 | 0.81 | NR4A2 (0.64) | GPR84ALDH1A1KMT2AHAT1EP300 | |
| SCHEMBL3174159 | 0.81 | ALDH1A1 (0.60) | ALDH1A1KMT2AHAT1EP300NR4A2 | |
| SCHEMBL25742000 | 0.80 | GPR84 (0.45) | GPR84TDO2KDM4EHAT1EP300 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016371-A1 | Indole Compounds | GLAXO GROUP LIMITED (GB) | 2010-01-21 | — | — | US | disclosed |
| US-20100016371-A1 | Indole Compounds | GLAXO GROUP LIMITED (GB) | 2010-01-21 | — | — | US | disclosed |
| US-20100016371-A1 | Indole Compounds | GLAXO GROUP LIMITED (GB) | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016371-A1 | Indole Compounds | IDO1, TPH1, IDO2 | GPR84 1787/4885TDO2 44/4885ALDH1A1 728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.